Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 7,627 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Hypertension
Interventions: Firibastat, Placebo; Drug
Lead sponsor: Quantum Genomics SA; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Huntington Beach, California • Tustin, California + 11 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions: Inhaled Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 91
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more

Conditions: Osteoarthritis
Interventions: Not listed
Lead sponsor: Heekin Orthopedic Research Institute; Other
Eligibility: 21 Years to 93 Years
Enrollment: 942 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Parkinson Disease
Interventions: sumanirole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 60 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 56
States / cities: Phoenix, Arizona • Glendale, California • Irvine, California + 51 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: WIN378, Placebo; Drug
Lead sponsor: Windward Bio; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Jacksonville, Florida • Miami Lakes, Florida + 6 more

Conditions: Recurrent Pericarditis, Heart Diseases, Pericarditis
Interventions: KPL-387; Drug
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 17 more

Conditions: Colorectal Neoplasms
Interventions: MicroOrganoSphere (MOS) drug screen; Device
Lead sponsor: Xilis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Placebo, AZD0780; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Inglewood, California • Northridge, California • Pomona, California + 20 more

Conditions: Presbyopia
Interventions: BRIMOCHOL™ PF, Carbachol PF, Brimonidine tartrate; Drug
Lead sponsor: Visus Therapeutics; Other
Eligibility: 45 Years to 80 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Glendale, California • Rancho Cordova, California • Jacksonville, Florida + 10 more

Conditions: Clostridium Difficile
Interventions: SER-109, Placebo; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Oceanside, California • Sacramento, California • Ventura, California + 26 more

Conditions: Neuroblastoma
Interventions: carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 12 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more

Conditions: Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions: Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy; Drug · Radiation · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2037
U.S. locations: 679
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more

Conditions: Chronic Constipation, Constipation
Interventions: Linaclotide 290 micrograms, Linaclotide 145 micrograms, Matching placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 146
States / cities: Chandler, Arizona • Glendale, Arizona • Goodyear, Arizona + 125 more

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: Douglas W. Johnson MD, FACR; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Autosomal Dominant Hypocalcemia
Interventions: Not listed
Lead sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: Up to 90 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 9
States / cities: Oakland, California • Aurora, Colorado • Jacksonville, Florida + 6 more

Conditions: Type 1 Diabetes
Interventions: TZIELD (teplizumab-mzwv); Drug
Lead sponsor: Sanofi; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 37
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 32 more

Conditions: Migraine
Interventions: BHV-2100, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 60
States / cities: Gilbert, Arizona • Encino, California • Los Alamitos, California + 57 more

Conditions: Psoriatic Arthritis
Interventions: Apremilast 20mg, Apremilast 30mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 30
States / cities: Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more

Conditions: Atopic Dermatitis
Interventions: tapinarof cream, 1%, vehicle cream; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 2 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 57
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 49 more

Conditions: Non Small Cell Lung Carcinoma, c-MET
Interventions: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more

Conditions: Bipolar Disorder
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 41
States / cities: Birmingham, Alabama • Anaheim, California • Glendale, California + 38 more

Conditions: Tachycardia, Ventricular, Implantable Cardioverter Defibrillator (ICD), Fibrillation, Ventricular, Syncope
Interventions: Implanted Device; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 31
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 28 more

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Dihydroergotamine, Placebos; Drug
Lead sponsor: Satsuma Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more

Search by objective public record fields.

Firibastat in Treatment-resistant Hypertension

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Total Hip Registry

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

Transition to KPL-387 Monotherapy Dosing & Administration Study

MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Non-Invasive Biomarkers For Early Detection Of Lung Cancers

ADH1 and ADH2 Disease Monitoring Study (DMS)

Registry for Stage 2 Type 1 Diabetes

Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

PREPARE - Primary Prevention Parameters Evaluation

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine